Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of November 2025, with a specific report date of November 18, 2025. The filing serves to disclose a significant regulatory milestone rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a specific event and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the receipt of regulatory approval in Switzerland for the Company's ProSense Cryoablation System. This approval covers indications for the treatment of breast, lung, liver, and kidney cancer.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not provide specific financial guidance, updated outlook figures, or detailed risk factors within the text of this Form 6-K. The document focuses solely on the announcement of the Swiss regulatory approval.
Investor Verification Checklist
- Verify the specific scope of the Swiss regulatory approval for the ProSense Cryoablation System across breast, lung, liver, and kidney cancer indications.
- Confirm the commercialization timeline and strategy for the Swiss market following this approval.
- Review the full text of the press release (Exhibit 99.1) for any additional details on market access or reimbursement status in Switzerland.
- Check subsequent filings for any financial impact or revenue recognition related to this new market entry.